Biotechnology News and Research

RSS

Acorda Therapeutics receives U.S. patent allowance for aminopyridine compositions

Acorda Therapeutics, Inc. today announced that the United States Patent and Trademark Office (USPTO) has allowed U.S. Patent Application No. 11/102,559 entitled "Method of Using Sustained Release Aminopyridine Compositions."

10 Aug 2011

Akela announces new corporate focus on PharmaForm

Akela Pharma, Inc. today announced a new strategic focus on its profitable pharmaceutical contract manufacturing business, PharmaForm, LLC.

9 Aug 2011

Criterium to manage Senesco's SNS01-T Phase Ib/2a multiple myeloma study

Senesco Technologies, Inc. today announced that it has contracted Criterium, Inc. to manage the operational aspects of its Phase Ib/2a clinical study of SNS01-T, the Company's lead therapeutic candidate for the treatment of multiple myeloma.

9 Aug 2011

Eurofins Optimed, Spaulding Clinical announce joint partnership agreement

Eurofins Optimed Clinical Research, an experienced European clinical research service provider and Spaulding Clinical Research, LLC., US-based, leading-edge Clinical Pharmacology, Cardiac Core Lab, and Medical Device Manufacturer, announce a joint partnership agreement.

9 Aug 2011

SUNY Downstate signs new three-year agreement with Aetna

Aetna and the State University of New York (SUNY) Downstate Medical Center announced a new agreement for SUNY Downstate's resumed participation in the Aetna network, and the continuing participation of University Hospital of Brooklyn's recently acquired Long Island College Hospital campus.

9 Aug 2011

22nd Century initiates enrollment in Phase II-B clinical trial of X-22 for smoking cessation

22nd Century Group, Inc., a company focused on smoking cessation and tobacco harm reduction products, today announced that its wholly-owned subsidiary, 22nd Century Limited, LLC, enrolled the first patients in its Phase II-B clinical trial for X-22, a prescription smoking cessation aid in development.

8 Aug 2011

AMRI second quarter total revenue increases 9% to $53.9 million

AMRI today reported financial and operating results for the second quarter ended June 30, 2011.

8 Aug 2011

FDA accepts Teva's NDA for BDP Nasal HFA to treat allergic rhinitis

Teva Pharmaceutical Industries Ltd. today announced that the U.S. Food and Drug Administration has accepted for filing Teva's New Drug Application (NDA) for beclomethasone dipropionate hydrofluoroalkane (BDP Nasal HFA), a nasal aerosol corticosteroid in development for the treatment of seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR).

8 Aug 2011

Unigene second quarter revenue decreases to $2.5 million

Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced second quarter financial results for the period ended June 30, 2011. The Company highlighted significant progress achieved in the second quarter with the continued execution of its turnaround strategy.

8 Aug 2011

NanoLogix BNP and BNF Quick Test kits detect, identify Group B Strep in four to six hours

NanoLogix, a biotechnology innovator in the rapid detection and identification of live-cell bacteria and microorganisms, announced today that the American Journal of Perinatology has published a peer-reviewed paper from the University of Texas Health Science Center - Houston confirming NanoLogix BioNanoPore (BNP) and BioNanoFilter (BNF) Quick Test technology detect and identify Group B Strep in four to six hours.

8 Aug 2011

Affymetrix announces commercialization of next-generation human transcriptome array

Affymetrix, Inc. today announced commercialization of the next-generation human transcriptome array demonstrated by Stanford University researchers to be superior to mRNA sequencing (RNA-Seq) in gene expression profiling studies.

8 Aug 2011

Scientist urges federal officials to decide on genetically engineered salmon for consumption

A Purdue University scientist is urging federal officials to decide whether genetically engineered salmon would be allowed for U.S. consumption and arguing that not doing so may set back scientific efforts to increase food production.

6 Aug 2011

Idera second quarter net loss increases to $6.3 million

Idera Pharmaceuticals, Inc. today reported financial results for the second quarter ended June 30, 2011. Idera is a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-Like receptors (TLRs).

5 Aug 2011

Scientists identify reasons behind why we are unable to recognise faces

The research, led by Dr Clea Warburton and Dr Gareth Barker in the University's School of Physiology and Pharmacology and published in the Journal of Neuroscience, has investigated why we can recognise faces much better if we have extra clues as to where or indeed when we encountered them in the first place.

5 Aug 2011

European Union grant to support clinical research and education at ICRC

Mayo Clinic will receive $10 million in research funding from the European Union (EU) as part of a $220 million grant to its collaborator, the St. Anne's University Hospital in Brno, the Czech Republic.

5 Aug 2011

BD Biosciences, Fluidigm to co-host public seminars on isolation and analysis of single cells

Fluidigm Corporation announced today a collaboration with BD Biosciences, a segment of BD, to co-host a public seminar series on the isolation and analysis of single cells. Entitled A Powerful Technique for Single-Cell Analysis, the public seminar series will showcase cell isolation using the BD FACSAria III Cell Sorter and analysis using the Fluidigm BioMark HD System.

From BD (Becton, Dickinson and Company) 5 Aug 2011